tbuckley/cabot-search huggingface dataset:
TCT-483 Influence of Multivessel Disease and Impact of Complete Revascularization in Left Ventricular Function Recovery Following STEMI
Authors: Luis Ortega-Paz, Juan Miguel Goyeneche, Teresa López, Xavier Bosch, Salvatore Brugaletta, Jany Rodríguez, Manel Sabate, Jose Tomás Ortiz-Pérez
Journal: Journal of the American College of Cardiology (2019)
Towards better evidence-informed global action: lessons learnt from the Lancet series and recent developments in physical activity and public health
Authors: Ding Ding, Andrea Ramirez Varela, Adrian E Bauman, Ulf Ekelund, I-Min Lee, Gregory Heath, Peter T Katzmarzyk, Rodrigo Reis, Michael Pratt
Journal: British Journal of Sports Medicine (2019)

In the past few decades, the field of physical activity has grown and evolved in scope, depth, visibility and impact around the world. Global progress has been observed in research and practice in physical activity regarding surveillance, health outcomes, correlates/determinants, interventions, translation and policy. The 2012 and 2016 Lancet series on physical activity provide some of the most comprehensive global analysis on various topics within physical activity. Based on the Lancet series and other key developments in the field, literature searches, and expert group meetings and consultation, we provide a global summary on the progress of, gaps in and future directions for physical activity research in the following areas: (1) surveillance and trends, (2) correlates and determinants, (3) health outcomes and (4) interventions, programmes and policies. Besides lessons learnt within each specific area, several recommendations are shared across areas of research, including improvement in measurement, applying a global perspective with a growing emphasis on low-income and middle-income countries, improving inclusiveness and equity in research, making translation an integral part of research for real-world impact, taking an ‘upstream’ public health approach, and working across disciplines and sectors to co-design research and co-create solutions. We have summarised lessons learnt and recommendations for future research as ‘roadmaps’ in progress to encourage moving the field of physical activity towards achieving population-level impact globally.
Pediatric Psychiatric Emergency Department Utilization and Fine Particulate Matter: A Case-Crossover Study
Authors: Cole Brokamp, Jeffrey R. Strawn, Andrew F. Beck, Patrick Ryan
Journal: Environmental Health Perspectives (2019)

Background: Acute exposure to ambient particulate matter <2.5μm in aerodynamic diameter (PM2.5) has been associated with adult psychiatric exacerbations but has not been studied in children. Objectives: Our objectives were to estimate the association between acute exposures to ambient PM2.5 and psychiatric emergency department (ED) utilization and to determine if it is modified by community deprivation. Methods: We used a time-stratified case-crossover design to analyze all pediatric, psychiatric ED encounters at Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio, from 2011 to 2015 (n=13,176). Conditional logistic regression models adjusted for temperature, humidity, and holiday effects were used to estimate the odds ratio (OR) for a psychiatric ED visit 0–3 d after ambient PM2.5 exposures, estimated at residential addresses using a spatiotemporal model. Results: A 10-μg/m3 increase in PM2.5 was associated with a significant increase in any psychiatric ED utilization 1 [OR=1.07 (95% CI: 1.02, 1.12)] and 2 [OR=1.05 (95% CI: 1.00, 1.10)] d later. When stratified by visit reason, associations were significant for ED visits related to adjustment disorder {e.g., 1-d lag [OR=1.24 (95% CI: 1.02, 1.52)] and suicidality 1-d lag [OR=1.44 (95% CI: 1.03, 2.02)]}. There were significant differences according to community deprivation, with some lags showing stronger associations among children in high versus low deprivation areas for ED visits for anxiety {1-d lag [OR=1.39 (95% CI: 0.96, 2.01) vs. 0.85 (95% CI: 0.62, 1.17)] and suicidality same day [OR=1.98 (95% CI: 1.22, 3.23) vs. 0.93 (95% CI: 0.60, 1.45)]}. In contrast, for some lags, associations with ED visits for adjustment disorder were weaker for children in high-deprivation areas {1-d lag [OR=1.00 (95% CI: 0.76, 1.33) vs. 1.50 (95% CI: 1.16, 1.93)]}. Discussion: These findings warrant additional research to confirm the associations in other populations. https://doi.org/10.1289/EHP4815
TCT-541 Validation of the Academic Research Consortium–High Bleeding Risk Criteria for Patients Undergoing Percutaneous Coronary Intervention
Authors: Davide Cao, Roxana Mehran, Rishi Chandiramani, Anastasios Roumeliotis, Ridhima Goel, Moritz Blum, Samantha Sartori, Rachel Singleton, Giulio Stefanini, George Dangas, Usman Baber, Asaad Khan, Jason Kovacic, Joseph Sweeny, Prakash Krishnan, Nitin Barman, Samin Sharma, Annapoorna Kini
Journal: Journal of the American College of Cardiology (2019)
TCT-294 Clinical Outcomes in Women and Minorities According to the Urgency of Percutaneous Coronary Intervention
Authors: Davide Cao, Wayne Batchelor, Rishi Chandiramani, Anastasios Roumeliotis, Moritz Blum, Ridhima Goel, Melissa Aquino, Amir Malik, Marcella Press, Paul Underwood, Dominic Allocco, Roxana Mehran
Journal: Journal of the American College of Cardiology (2019)
Reweighing the Ethical Tradeoffs in the Involuntary Hospitalization of Suicidal Patients
Authors: Adam Borecky, Calvin Thomsen, Alex Dubov
Journal: The American Journal of Bioethics (2019)

Suicide is the 10th leading cause of death in the United States and the second cause of death among those ages 15-24 years. The current standard of care for suicidality management often involves an involuntary hospitalization deemed necessary by the attending psychiatrist. The purpose of this article is to reexamine the ethical tradeoffs inherent in the current practice of involuntary psychiatric hospitalization for suicidal patients, calling attention to the often-neglected harms inherent in this practice and proposing a path for future research. With accumulating evidence of the harms inherent in civil commitment, we propose that the relative value of this intervention needs to be reevaluated and more efficacious alternatives researched. Three arguments are presented: (1) that inadequate attention has been given to the harms resulting from the use of coercion and the loss of autonomy, (2) that inadequate evidence exists that involuntary hospitalization is an effective method to reduce deaths by suicide, and (3) that some suicidal patients may benefit more from therapeutic interventions that maximize and support autonomy and personal responsibility. Considering this evidence, we argue for a policy that limits the coercive hospitalization of suicidal individuals to those who lack decision-making capacity.
Letter to the Editor: Lipoprotein Subparticles and Cardiovascular Risk in Liver Transplantation: More Details, More Significance
Authors: Pusen Wang, Lin Zhong
Journal: Hepatology (2019)

Potential conflict of interest: Nothing to report. To the Editor: We read with great interest the article of Siddiqui et al.1 in Hepatology, which demonstrated that serum concentration of small dense low‐density lipoprotein cholesterol (sdLDL‐C) independently predicted cardiovascular disease (CVD) events. Indeed, this study provides a potential useful clinical tool in stratifying patients at risk for CVD events after liver transplantation (LT). We would, however, like to raise the following concerns. First, as shown in Table 1 of the study of Siddiqui et al., significant differences existed in baseline clinical characteristics, such as hepatitis C, nonalcoholic steatohepatitis, cardiometabolic conditions, alanine aminotransferase, aspartate aminotransferase, and bilirubin (all P < 0.05). Supporting Table S1 also showed distinctly different baseline characteristic with etiology of liver disease. These results suggested an unbalanced condition between these groups. The specificity and sensitivity of sdLDL‐C predicting CVD events may differ by the type of liver disease. The baseline of level of sdLDL‐C also varies by the etiology of liver disease. Therefore, we suggest that the authors perform a well‐matched analysis or subgroup analysis that enables better balance between groups across all putative risk factors. In addition, from a statistical point of view, there are too many risk factors in the multivariate analysis because CVD events occurred only in 20 patients after LT. Second, the variables on patients’ baseline characteristics investigated in this study seemed far from enough. For instance, history of CVD, intensive care unit status, ventilator status, pre‐LT hospitalization, calculated Model for End‐Stage Liver Disease score, portal vein thrombosis, cold ischemia time, donor body mass index, and donor age are also potential risk factors that would probably be associated with post‐LT CVD events.2 Therefore, we suggested that some essential variables be supplemented here. Third, although only post‐LT lipoprotein profile predicted CVD events independently, we still think it is worthy to analyze pre‐LT lipoprotein profile or changes in individuals’ lipoprotein levels after LT. Moreover, it seems that the authors chose 25 mg/dL as the cutoff value of sdLDL‐C to generate same number of patients in each group. We suggest that the authors perform receiver operating characteristic curve analysis to set the cutoff value of sdLDL‐C, which enables better sensitivity and specificity. In summary, this study by Siddiqui et al. is a great work focusing on CVD events after LT. However, because of its observational nature and heterogeneity of the patient population, it is vital to conduct high‐quality multicenter studies to assess the impact of sdLDL‐C on CVD events after LT.
TCT-645 The Importance of Coronary Revascularization and Guideline-Directed Medical Therapy (GDMT) in Elderly With Non–ST Elevation Acute Coronary Syndrome (NSTE-ACS)
Authors: Jonathan Fang, Anthony Wong, Kwong Yue Eric Chan, Arthur Yung, Catherine Shea, Timothy Un, Michael Sze, Yui-Ming Lam, Hung-Fat Tse, Ki-Wan Kelvin Chan, Cheung Chi Simon Lam, Chor Cheung Tam
Journal: Journal of the American College of Cardiology (2019)
Annals Graphic Medicine - Dr. Mom: What I Learned at Grand Rounds
Authors: Grace E. Farris
Journal: Annals of Internal Medicine (2019)

Web Exclusives1 October 2019Annals Graphic Medicine - Dr. Mom: What I Learned at Grand RoundsFREEGrace E. Farris, MDGrace E. Farris, MDMount Sinai School of Medicine, New York, New York (G.E.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G19-0049 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Mount Sinai School of Medicine, New York, New York (G.E.F.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G18-0042.Author/Illustrator Information: Grace E. Farris, MD, is an assistant professor of medicine at Icahn School of Medicine at Mount Sinai and chief of hospital medicine at Mount Sinai West hospital in New York, New York. You can view her work at her Web site: www.farrisgrace.com.About Dr. Mom: In Dr. Mom, physician and cartoonist Grace Farris examines work–life balance while mothering and doctoring. Dr. Mom appears monthly in Annals Graphic Medicine at Annals.org. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 2019Volume 171, Issue 7Page: W34-W37KeywordsConflicts of interestDisclosureHospital medicineHospitalists ePublished: 1 October 2019 Issue Published: 1 October 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
TCT-815 Does Addition of Percutaneous Left Ventricular Decompression Therapy With Impella Affect Clinical Outcomes in Cardiogenic Shock Patients on Venoarterial Extracorporeal Membrane Oxygenation? A Nationwide Analysis
Authors: Syed Zaid, Aaqib Malik, Cenap Undemir, Joshua Goldberg, Hasan Ahmad
Journal: Journal of the American College of Cardiology (2019)
TCT-836 The Ratio Serum Creatinine/Serum Cystatin C as a Predictor of Ischemic Risk in Elderly Patients With Coronary Artery Disease
Authors: Hak Seung Lee, You Jeong Ki, Jeehoon Kang, Jung-Kyu Han, Han-Mo Yang, Kyung Woo Park, Hyun-Jae Kang, Bon-Kwon Koo, Hyo-Soo Kim
Journal: Journal of the American College of Cardiology (2019)
2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease
Authors: Karen K. Stout, Curt J. Daniels, Jamil A. Aboulhosn, Biykem Bozkurt, Craig S. Broberg, Jack M. Colman, Stephen R. Crumb, Joseph A. Dearani, Stephanie Fuller, Michelle Gurvitz, Paul Khairy, Michael J. Landzberg, Arwa Saidi, Anne Marie Valente, George F. Van Hare
Journal: Journal of the American College of Cardiology (2018)
TCT-322 Outcome in Patients Undergoing High-Risk PCI Using Impella Circulatory Support: 10-Year Experience
Authors: Vincenzo Vetrugno, Muhammad Waqas, Kully Sandhu, Anthony Mechery, M. Adnan Nadir, Sudhakar George, Alexander Zaphiriou, Sern Lim, Peter Ludman, Sagar Doshi, John Townend, Sohail Khan
Journal: Journal of the American College of Cardiology (2019)
Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial
Authors: Amylou C. Dueck, Howard I. Scher, Antonia V. Bennett, Gina L. Mazza, Gita Thanarajasingam, Gisela Schwab, Aaron L. Weitzman, Lauren J. Rogak, Ethan Basch
Journal: JAMA Oncology (2019)

Standard adverse event (AE) reporting in oncology clinical trials has historically relied on clinician grading, which prior research has shown can lead to underestimation of rates of symptomatic AEs. Industry sponsors are beginning to implement in trials the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), which was developed to allow patients to self-report symptomatic AEs and improve the quality of symptomatic AE detection.To evaluate the feasibility of implementing PRO-CTCAE in a prespecified correlative analysis of the phase 3 COMET-2 trial and enumerate statistically significant between-group differences in symptomatic AEs using PRO-CTCAE and the CTCAE.This correlative study of 119 men in the randomized, double-blind, placebo-controlled phase 3 COMET-2 trial with metastatic castration-resistant prostate cancer who had undergone at least 2 prior lines of systemic treatment was conducted from March 2012 to July 2014. Participants completed PRO-CTCAE items using an automated telephone system from home prior to treatment and every 3 weeks during treatment. Statistical analysis was performed from May 2018 to June 2019.The proportion of patients who completed expected PRO-CTCAE self-reports was computed as a measure of feasibility.Among the 119 men in the study (median age, 65 years [range, 44-80 years]), 534 of 587 (91.0%) expected PRO-CTCAE self-reports were completed, with consistently high rates of completion throughout participation. Rates of self-report adherence were similar between groups (cabozantinib s-maleate, 286 of 317 [90.2%]; and mitoxantrone hydrochloride-prednisone, 248 of 270 [91.9%]). Of 12 measured, patient-reported PRO-CTCAE symptomatic AEs, 4 reached statistical significance when comparing the proportion of patients with at least 1 postbaseline score greater than 0 between groups (differences ranged from 20.1% to 34.1% with higher proportions in the cabozantinib group; all P < .05), and use of a method for accounting for preexisting symptoms at baseline yielded 7 AEs with statistically significant differences between groups (differences ranged from 20.5% to 41.2% with higher proportions in the cabozantinib group; all P < .05). In the same analysis using investigator-reported CTCAE data, no statistically significant differences were found between groups for any symptomatic AEs.PRO-CTCAE data collection was feasible and improved the accuracy of symptomatic AE detection in a phase 3 cancer trial. This analysis adds to mounting evidence of the feasibility and value of patient-reported AEs in oncology, which should be considered for inclusion in cancer trials that incorporate AE evaluation.ClinicalTrials.gov identifier: NCT01522443.
Association Between Thrombolytic Treatment and the Prognosis of Hemodynamically Stable Patients With Major Pulmonary Embolism
Authors: Stavros Konstantinides, Annette Geibel, Manfred Olschewski, Fritz Heinrich, Klaus Grosser, Klaus Rauber, Stein Iversen, Matthias Redecker, Joachim Kienast, Hanjörg Just, Wolfgang Kasper
Journal: Circulation (1997)

Background Thrombolytic treatment has been shown to accelerate resolution of major pulmonary embolism and lead to a rapid improvement of right-side hemodynamics. However, the association between these favorable effects and the clinical outcome of patients who have no severe hemodynamic compromise at presentation remains unknown. Methods and Results The present multicenter registry included 719 consecutive patients with major pulmonary embolism according to clinical, echocardiographic, scintigraphic, and cardiac catheterization criteria. Symptom onset was acute (&lt;48 hours) in 63% of patients. All patients were hemodynamically stable (ie, without evidence of cardiogenic shock) at presentation. Primary thrombolytic treatment (within 24 hours of diagnosis) was given to 169 patients (23.5%), whereas the remaining 550 patients were initially treated with heparin alone. Overall 30-day mortality was significantly lower in the patients who received thrombolytic agents (4.7 versus 11.1%, P =.016). Clinical factors associated with a higher death rate were syncope ( P =.012), arterial hypotension ( P =.021), history of congestive heart failure ( P =.013), and chronic pulmonary disease ( P =.032). However, only primary thrombolysis was found by multivariate analysis to be an independent predictor of survival (odds ratio for in-hospital death, 0.46; 95% confidence interval, 0.21 to 1.00). Patients who underwent early thrombolytic treatment had a reduced rate of recurrent pulmonary embolism (7.7 versus 18.7%, P &lt;.001) but also a higher frequency of major bleeding episodes (21.9% versus 7.8%, P &lt;.001). Cerebral bleeding occurred in 2 patients in each treatment group, and 1 patient in each group died of a bleeding complication. Conclusions The results of our study suggest that thrombolysis may favorably affect the clinical outcome of hemodynamically stable patients with major pulmonary embolism.
TCT-794 Impact of the Distal Radial Artery Approach for Diagnostic Coronary Catheterization in Nursing Service
Authors: Shiho Moriyama, Shihomi Tagaito, Yukio Mizuguchi, Takeshi Yamada, Norimasa Taniguchi, Shunsuke Nakajima, Tetsuya Hata, Akihiko Takahashi
Journal: Journal of the American College of Cardiology (2019)
Endoscopic vacuum therapy for esophageal anastomotic leak: combining guidewire with overtube technique
Authors: Sofia Saraiva, Susana Mão-de-Ferro, Isadora Rosa, António Dias Pereira
Journal: Endoscopy (2019)

A 70-year-old man with an adenocarcinoma of the gastroesophageal junction developed an anastomotic leak three weeks after Ivor Lewis esophagectomy. Initially, a fully covered metal stent was placed, but after stent redraw, endoscopy revealed the persistence of the leak and an associated 5-cm cavity ([Fig. 1]).
Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies
Authors: Gerard J Criner, Bartolome R Celli, Dave Singh, Alvar Agusti, Alberto Papi, Maria Jison, Natalya Makulova, Vivian H Shih, Laura Brooks, Peter Barker, Ubaldo J Martin, Paul Newbold
Journal: The Lancet Respiratory Medicine (2019)
TCT-316 Clinical Outcomes After Left Main Coronary Artery Revascularization by PCI or CABG in Current, Former, and Never Smokers: Analysis From the EXCEL Trial
Authors: Bahira Shahim, Bjorn Redfors, Shmuel Chen, Marie-Claude Morice, David Taggart, Bernard Gersh, John Puskas, David Kandzari, Bela Merkely, Aaron Crowley, Patrick Serruys, A. Pieter Kappetein, Joseph Sabik, Ori Ben-Yehuda, Gregg Stone
Journal: Journal of the American College of Cardiology (2019)
TCT-450 Impact of Atrial Fibrillation on Short-Term Outcomes in Patients Undergoing Percutaneous Mitral Valve Repair
Authors: Mohamed Gad, Anas Saad, Keerat Rai Ahuja, Najdat Bazarbashi, Antonette Karrthik, Simrat Kaur, Johnny Chahine, Manpreet Kaur, Yasser Sammour, Amer N. Kadri, Samir Kapadia
Journal: Journal of the American College of Cardiology (2019)
TCT-236 Coronary Artery Bypass Grafting in Patients Presenting With ST-Segment Elevation Myocardial Infarction: The Optimal Timing and Impact on Outcomes: Insights From the TOTAL Trial
Authors: Matthias Bossard, Elie Akl, Vladimir Dzavik, John Cairns, Shamir Mehta, Madhu Natarajan, Shahar Lavi, Raymond Leung, Anthony Fung, Richard Whitlock, Asim Cheema, Kari Niemela, Brandi Meeks, Warren Cantor, Sasko Kedev, Goran Stankovic, Raul Moreno, Sanjit Jolly
Journal: Journal of the American College of Cardiology (2019)
Results of a phase II multicenter study of minimally invasive esophagectomy (Eastern Cooperative Oncology Group Study E2202)
Authors: J. Luketich, A. Pennathur, P. J. Catalano, S. J. Swanson, A. L. de Hoyos, M. A. Maddaus, N. Nguyen, A. B. Benson, H. C. Fernando
Journal: Journal of Clinical Oncology (2009)

4516 Background: The incidence of esophagogastric adenocarcinoma (EAC) is increasing at an alarming rate in the United States. Definitive treatment may require a combination of surgery (esophagectomy), chemotherapy and radiation. Operative mortality rates after esophagectomy have been reported as high as 8–23% (NEJM 2003). Minimally invasive esophagectomy (MIE) may decrease morbidity and mortality. Previous single institution studies have demonstrated successful outcomes with MIE. The primary aim of this cooperative group protocol ECOG 2202 was to assess the feasibility of MIE in a multi-institutional setting. Methods: We conducted a prospective phase II trial with a two-stage design. Thirty-five patients entered the first stage, followed by an interim analysis. Next, the study continued to the second stage and full accrual. The primary endpoint was 30-day mortality. Secondary endpoints included complications, duration of intensive care unit (ICU) stay, lymph node (LN) count and clinical outcomes at 3 years. Results: We entered 106 patients (men 84%; women 22%; median age 64, range 36–83) into the study from 16 institutions in the United States (ECOG, CALGB, ACOSOG). Neoadjuvant chemotherapy was administered in 35 (33%) and radiation in 26 (25%). MIE was performed in 99 patients. Final pathology included high-grade dysplasia (n=11), and EAC (n=88). Complications included an overall 30-day mortality rate of 2% (2/106),. Other major complications included pneumonia (4.9%) and anastomotic leak (7.8%). Median ICU stay was 2 days; median LN count was 20. At a mean follow-up of 19 months, the estimated 3-year overall survival for the entire cohort was 50% (95% Confidence interval 35–65%). Stage specific survival was similar to open series. Conclusions: This phase II study demonstrates that MIE is safe and feasible in a multi-center trial, with low perioperative mortality rate and morbidity. Oncologic outcomes are similar to open esophagectomy. This is the first report of a multicenter trial of minimally invasive esophagectomy. No significant financial relationships to disclose.